proteomic approaches to large human proteinprotein inter- action networks, Colland used the two-hybrid system to screen for Smad. Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser. This approach is based on the idea that lowering the dosage of a single gene from two copies to one in diploid yeast yields a heterozygote that is sensitized to any drug that acts on the product of this gene.Seven cheers for technology. The gene was judged to be deterministic of unidirectional gene ex- pression and for more than 50 years, the bulk of genomics research was guided by this model. Hence, changes in the tissue concentration of the drugreceptor complexes would be expected to par- allel changes in the concentration of free drugs in the tissue water bathing them, and because the tissue water and plasma water are in rapid equilibrium, changes in the complex. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M,. Numerous adverse drug reactions and interactions attributable to drug- metabolizing enzyme traits vary greatly from one population to another. Structural analysis by MS was accomplished by ionizing a compound of interest with a short burst coupon code store voguish of energy from an ion beam that caused its fragmentation with the formation of positively charged ions of the compound. Toxicology rethinks its central belief. Hence, it is reasonable to expect that drug transporter pharmacogenetics and drug- metabolizing enzyme pharmacogenetics taken together may be a better predictor of individual variation in drug efcacy and toxicity than either one alone. Proc Natl Acad Sci USA 1989; 86(23 95549557. Van der Hooft CS, Sturkenboom MC, van Grootheest K, Kingma HJ, Stricker. The gene structure, tissue-specic expression, chromosomal location, and regulation of RGS proteins in mammalian systems are as yet at an early stage of investigation, and the evidence for the physiological roles of RGS proteins as they are currently perceived comes mainly from model studies. CYP2C9 explains that approximately 610 of the variation in dose and genotyping prior to warfarin treatment could benet patients by reducing the risk of bleeding, especially during the high-risk period of therapy initiation.